DUBLIN--(BUSINESS WIRE)--The "Global Cancer Gene Therapy Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The global cancer gene therapy market is anticipated to grow at a substantial CAGR of 23.1% during the forecast period. One of the major factors that are fueling the market includes the rising pool of population with cancer patients coupled with an increasing geriatric population base. Globally there is a rise in cancer patients each year.
Several initiatives are being launched about gene therapy catering to treating and reducing the number of cancer incidences across the globe. For instance, in October 2021, the National Institutes of Health, the US Food and Drug Administration (US FDA), ten pharmaceutical companies, and five non-profit groups have teamed up to speed up gene therapy development for the 30 million Americans who suffer from a rare disease.
Such measures are expected to boost demand for gene therapy, boosting the market growth. Additionally, in October 2019, GammaDelta Therapeutics announced the formation of the spinout company Adaptate Biotherapeutics. Adaptate develops therapeutic antibodies that can modulate the activity of gamma delta T-cells to trigger an immune response to fight cancer.
The global cancer gene therapy market can be segmented based on therapy and end-users. Based on the therapy, the cancer gene therapy market is segmented into gene transfer immunotherapy, oncolytic virotherapy, and gene-induced immunotherapy.
The gene-induced immunotherapy is further segmented as delivery of cytokines gene and delivery of tumor antigen gene. Based on end-users, the global cancer gene therapy market is diversified as hospitals, research institutes, and biotech companies. Among the therapy, the immunotherapy segment is expected to hold a considerable share in the global market owing to the rise in advancement of gene-induced immunotherapy research along with various R&D activities.
Market Segmentation
- Global Cancer Gene Therapy Market Research and Analysis by Therapy.
- Global Cancer Gene Therapy Market Research and Analysis by End-Users.
The Report Covers
- Comprehensive research methodology of the global cancer gene therapy market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global cancer gene therapy market.
- Insights about market determinants that are stimulating the global cancer gene therapy market.
- Detailed and extensive market segments with the regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Segmentation
5. Regional Analysis
6. Company Profiles
Companies Mentioned
- Achilles Therapeutics Ltd.
- Adaptimmune Therapeutics Plc
- American Gene Technologies International Inc.
- Avrobio Inc.
- Beigene, Ltd.
- Bluebird Bio, Inc.
- Celgene Corporation
- Cell Medica Ltd.
- Formula Pharmaceuticals, Inc.
- Genprex, Inc.
- Genvec Inc.
- GlaxosmithklinePLC
- Illumina, Inc.
- Inovio Pharmaceuticals, Inc.
- Jounce Therapeutics, Inc.
- Merck &Co., Inc.
- Morphogenesis, Inc.
- Oxford Biomedica Plc
- Sangamo Therapeutics, Inc.
- Sirion Biotech GmbH
- Spark Therapeutics Inc.
- Synergene Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/vwp2vu
